gemfibrozil has been researched along with Diabetes Mellitus, Type 2 in 56 studies
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 9.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 9.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 9.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| "To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)." | 9.08 | Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998) |
| " simvastatin and gemfibrozil in type 2 diabetic patients with dyslipidemia in Pakistani population." | 5.11 | Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes. ( Amir, K; Ashraf, R; Shaikh, AR, 2005) |
| "To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL cholesterol and a broad range of triglyceride values who participated in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT)." | 5.10 | Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Robins, SJ; Rubins, HB; Schaefer, EJ, 2003) |
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 5.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 5.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| "To compare the lipid-lowering efficacies of simvastatin and gemfibrozil in NIDDM patients with combined (mixed) hyperlipidemia (CHL) or isolated hypercholesterolemia (IHC)." | 5.08 | Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. ( Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ, 1998) |
| " In a double-blind, parallel, randomized study, lovastatin and gemfibrozil were compared in 102 diabetic patients with primary hypercholesterolemia; two-thirds of the patients were treated with oral hypoglycemic agents and one-third received diet therapy alone for their diabetes." | 5.06 | Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. ( Goldberg, R; La Belle, P; Ronca, P; Zupkis, R, 1990) |
| "Gemfibrozil is a PPAR-α ligand that inhibits the progression of atherosclerosis in insulin resistance type 2 diabetes mellitus (IR type 2 DM)." | 3.79 | Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. ( Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013) |
| "After study at entry, in 56 women (median age, 52 years), 36 with familial hypertriglyceridemia, to lower triglycerides, estrogens and SERMs (hormone treatment, HT) were stopped; a very low fat diet (<15% of calories), gemfibrozil (1." | 3.72 | An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. ( Glueck, CJ; Goldenberg, NM; Wang, P, 2003) |
| " An unusual dose-response pattern was observed in that at 6 mg/day CP-778,875 only increased HDL cholesterol by 3% and decreased HDL(2) cholesterol by 24%." | 2.73 | Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. ( Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG, 2008) |
| "Disease progression is associated with variation in AAT, and low AAT levels promote atherogenesis." | 2.71 | Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. ( Flavell, DM; Frick, MH; Humphries, SE; Jackson, R; Kesäniemi, YA; Martin, S; Nagl, S; Nieminen, MS; Pasternack, A; Steiner, G; Syvänne, M; Talmud, PJ; Taskinen, MR; Whitehouse, DB, 2003) |
| "Atorvastatin was more effective (P < 0." | 2.71 | Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. ( Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM, 2003) |
| "For this purpose, 22 patients with type 2 diabetes and combined dyslipidemia were randomized to treatment with either a statin or gemfibrozil for 3 months." | 2.70 | Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. ( Abbasi, F; Lamendola, C; Leary, E; McLaughlin, T; Reaven, GM, 2002) |
| "Treatment with gemfibrozil 600 mg twice daily for 4 months decreased S-Mg by 0." | 2.70 | Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients. ( Haenni, A; Lithell, H; Ohrvall, M, 2001) |
| "Gemfibrozil treatment significantly decreased plasma triglyceride concentration from 316+/-84 to 214+/-82 mg/dl (P < 0." | 2.69 | The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. ( Avogaro, A; Catapano, A; Miola, M; Piliego, T; Tiengo, A, 1999) |
| "3." | 2.68 | Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. ( Avogaro, A; Beltramello, P; Biffanti, S; Bonanome, A; Confortin, L; Crepaldi, G; Manzato, E; Marin, R; Tiengo, A; Zambon, S, 1995) |
| "Fifteen normotensive NIDDM patients with hypertriglyceridaemia (> 2." | 2.68 | Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? ( Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; van Eeden, AE; Weijers, RN, 1997) |
| "Patients with NIDDM have a two- to fourfold increased risk of macrovascular disease." | 2.67 | Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. ( Colwell, JA; Vinik, AI, 1993) |
| "We performed LDL analyses on 16 NIDDM patients with stable glycemic control." | 2.67 | Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. ( Kuusi, T; Lahdenperä, S; Taskinen, MR; Tilly-Kiesi, M; Vuorinen-Markkola, H, 1993) |
| "Compared with nondiabetic subjects, NIDDM patients had lower HDL cholesterol (P less than 0." | 2.67 | Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M, 1992) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| " Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation." | 2.41 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. ( Keating, GM; Ormrod, D, 2002) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| " In a twelve-week study, chronic administration of 3b in db/db mice resulted in sustained glycemic control, to a greater extent than liraglutide and semaglutide." | 1.56 | Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents. ( Chen, X; Fu, J; Han, J; Li, C; Yang, Q; Yin, J; Zhou, F, 2020) |
| "Metformin has a greater impact on BMI in responders of metformin compared to nonresponders." | 1.43 | The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin. ( Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A, 2016) |
| "Eruptive xanthoma (EX) is a very rare dermatosis mostly occurring due to high levels of serum triglycerides or uncontrolled diabetes mellitus." | 1.42 | First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. ( Acikgoz, SB; Kara, RO; Kosem, M; Solak, B, 2015) |
| "Patients with a diagnosis of type 2 diabetes and either a history of coronary artery disease or at least one other significant cardiovascular risk factor as defined by the American College of Physicians guidelines (i." | 1.34 | Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists. ( McGuire, H; Nathan, JP; Rosenberg, JM; Zerilli, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (7.14) | 18.7374 |
| 1990's | 21 (37.50) | 18.2507 |
| 2000's | 24 (42.86) | 29.6817 |
| 2010's | 6 (10.71) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Fruchart, JC | 2 |
| Santos, RD | 1 |
| Han, J | 1 |
| Fu, J | 1 |
| Yang, Q | 1 |
| Zhou, F | 1 |
| Chen, X | 1 |
| Li, C | 1 |
| Yin, J | 1 |
| Solak, B | 1 |
| Kara, RO | 1 |
| Acikgoz, SB | 1 |
| Kosem, M | 1 |
| Kashi, Z | 1 |
| Mahrooz, A | 1 |
| Kianmehr, A | 1 |
| Alizadeh, A | 1 |
| Béliard-Lasserre, S | 1 |
| Terra, SG | 1 |
| Francone, OL | 1 |
| Contant, CF | 1 |
| Gao, X | 1 |
| Lewin, AJ | 1 |
| Nguyen, TT | 1 |
| Dunn, FL | 1 |
| Sharma, AK | 1 |
| Raikwar, SK | 1 |
| Kurmi, MK | 1 |
| Srinivasan, BP | 1 |
| Keating, GM | 1 |
| Ormrod, D | 1 |
| McLaughlin, T | 1 |
| Abbasi, F | 1 |
| Lamendola, C | 1 |
| Leary, E | 1 |
| Reaven, GM | 2 |
| Duriez, P | 1 |
| Colagiuri, S | 1 |
| Best, J | 1 |
| Talmud, PJ | 1 |
| Martin, S | 1 |
| Steiner, G | 1 |
| Flavell, DM | 1 |
| Whitehouse, DB | 1 |
| Nagl, S | 1 |
| Jackson, R | 1 |
| Taskinen, MR | 5 |
| Frick, MH | 2 |
| Nieminen, MS | 1 |
| Kesäniemi, YA | 1 |
| Pasternack, A | 1 |
| Humphries, SE | 1 |
| Syvänne, M | 2 |
| Robins, SJ | 1 |
| Rubins, HB | 1 |
| Faas, FH | 1 |
| Schaefer, EJ | 1 |
| Elam, MB | 1 |
| Anderson, JW | 1 |
| Collins, D | 1 |
| Goldenberg, NM | 1 |
| Wang, P | 1 |
| Glueck, CJ | 1 |
| Wägner, AM | 2 |
| Jorba, O | 2 |
| Bonet, R | 1 |
| Ordóñez-Llanos, J | 2 |
| Pérez, A | 2 |
| Sahhar, NN | 1 |
| Ahmad, AT | 1 |
| Ammari, FL | 1 |
| Ajlouni, KM | 1 |
| März, W | 1 |
| Ashraf, R | 1 |
| Amir, K | 1 |
| Shaikh, AR | 1 |
| Davidson, MH | 1 |
| Rosenberg, JM | 1 |
| Zerilli, T | 1 |
| Nathan, JP | 1 |
| McGuire, H | 1 |
| Avogaro, A | 3 |
| Beltramello, P | 1 |
| Marin, R | 1 |
| Zambon, S | 2 |
| Bonanome, A | 1 |
| Biffanti, S | 1 |
| Confortin, L | 1 |
| Manzato, E | 2 |
| Crepaldi, G | 1 |
| Tiengo, A | 3 |
| Welborn, TA | 1 |
| Kahri, J | 1 |
| Vuorinen-Markkola, H | 4 |
| Tilly-Kiesi, M | 2 |
| Lahdenperä, S | 2 |
| Vinik, AI | 1 |
| Colwell, JA | 1 |
| Hilden, H | 1 |
| Yki-Järvinen, H | 1 |
| Kuusi, T | 1 |
| Fasching, P | 1 |
| Rohac, M | 1 |
| Liener, K | 1 |
| Schneider, B | 1 |
| Nowotny, P | 1 |
| Waldhäusl, W | 1 |
| Smulders, YM | 1 |
| van Eeden, AE | 1 |
| Stehouwer, CD | 1 |
| Weijers, RN | 1 |
| Slaats, EH | 1 |
| Silberbusch, J | 1 |
| Migdalis, IN | 1 |
| Gerolimou, B | 1 |
| Kozanidou, G | 1 |
| Voudouris, G | 1 |
| Hatzigakis, SM | 1 |
| Petropoulos, A | 1 |
| Tikkanen, MJ | 1 |
| Laakso, M | 1 |
| Ilmonen, M | 1 |
| Helve, E | 1 |
| Kaarsalo, E | 1 |
| Kilkki, E | 1 |
| Saltevo, J | 1 |
| O'Neal, DN | 1 |
| O'Brien, RC | 1 |
| Timmins, KL | 1 |
| Grieve, GD | 1 |
| Lau, KP | 1 |
| Nicholson, GC | 1 |
| Kotowicz, MA | 1 |
| Best, JD | 1 |
| Yoshinari, M | 1 |
| Asano, T | 1 |
| Kaori, S | 1 |
| Shi, AH | 1 |
| Wakisaka, M | 1 |
| Iwase, M | 1 |
| Fujishima, M | 1 |
| Kanters, SD | 1 |
| Algra, A | 1 |
| de Bruint, TW | 1 |
| Erkelens, DW | 1 |
| Banga, JD | 1 |
| Piliego, T | 2 |
| Catapano, A | 1 |
| Miola, M | 2 |
| Durrington, P | 1 |
| Ogunko, A | 1 |
| Oboubie, K | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Favaro, A | 1 |
| Gottardo, L | 1 |
| Pacini, G | 1 |
| Sacerdoti, D | 1 |
| de Kreutzenberg, S | 1 |
| Del Prato, S | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Haenni, A | 1 |
| Ohrvall, M | 1 |
| Lithell, H | 1 |
| Balogh, Z | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Kovács, P | 1 |
| Kakuk, G | 1 |
| Paragh, G | 1 |
| Schweitzer, M | 1 |
| Tessier, D | 1 |
| Vlahos, WD | 1 |
| Leiter, L | 1 |
| Collet, JP | 1 |
| McQueen, MJ | 1 |
| Harvey, L | 1 |
| Alaupovic, P | 1 |
| Whitelaw, DC | 1 |
| Smith, JM | 1 |
| Nattrass, M | 1 |
| Koskinen, P | 1 |
| Mänttäri, M | 1 |
| Manninen, V | 1 |
| Huttunen, JK | 1 |
| Heinonen, OP | 1 |
| Bell, DS | 1 |
| Wagenknecht, LE | 1 |
| Tong, N | 1 |
| Liang, J | 1 |
| Shen, DC | 1 |
| Fuh, MM | 2 |
| Shieh, SM | 1 |
| Chen, YD | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Goldberg, R | 1 |
| La Belle, P | 1 |
| Zupkis, R | 1 |
| Ronca, P | 1 |
| Garg, A | 1 |
| Grundy, SM | 1 |
| Liang, JZ | 1 |
| Li, Y | 1 |
| Chang, DM | 1 |
| Jeng, CY | 1 |
| Shian, LR | 1 |
| Ho, LT | 1 |
| Li, SH | 1 |
| Chou, TY | 1 |
| Liu, YF | 1 |
| Perng, JC | 1 |
| Han, HK | 1 |
| Chen, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes (T2DM)[NCT00577590] | 78 participants (Actual) | Interventional | 2003-10-31 | Completed | |||
| Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy[NCT00469911] | 18 participants (Actual) | Interventional | 2005-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00577590)
Timeframe: Baseline and 3 months
| Intervention | percent change (Mean) | |
|---|---|---|
| Plasma triglycerides women | Plasma triglycerides men | |
| Metformin | 16.0 | -10.0 |
| Metformin and Lovaza | -2.0 | -5.0 |
| Metformin and Rosiglitazone | -5.0 | 1.0 |
Participants first had MRS spectroscopy then the MRS spectroscopy images were compared to endomyocardial biopsy (NCT00469911)
Timeframe: 2 to 10 days
| Intervention | correlation co-efficient (Number) |
|---|---|
| Heart Transplant Patients | 0.97 |
10 reviews available for gemfibrozil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems; | 2002 |
HDL and triglyceride as therapeutic targets.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, T | 2002 |
Lipid-lowering therapy in people with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reducta | 2002 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diabetes Mellitus, Type 2; | 1994 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
29 trials available for gemfibrozil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabete | 2008 |
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hydroxym | 2002 |
Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.
Topics: 3' Untranslated Regions; Aged; Alleles; alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Amino A | 2003 |
Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Body Constitution; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Ty | 2003 |
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2003 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; | 2004 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibr | 2005 |
Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Insulin | 1995 |
Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity.
Topics: Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Coronary | 1993 |
Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin; | 1993 |
Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.
Topics: Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diterpenes; Female; Food; Gemfibrozil | 1993 |
Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Fatty | 1993 |
Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
Topics: Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Bli | 1993 |
Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study.
Topics: Aged; Blood Glucose; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fish Oils; | 1996 |
Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dise | 1997 |
Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia.
Topics: Administration, Oral; Arteriosclerosis; Blood Glucose; Carotid Artery Diseases; Carotid Artery, Comm | 1997 |
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes M | 1998 |
Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
Topics: Blood Coagulation; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Gemfib | 1998 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes | 1999 |
The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Bl | 1999 |
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Circulation; Diabetes Mellitus, Type 2; Endothelium, Vascular; Gemfibr | 2001 |
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfibrozil; Huma | 2001 |
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Topics: Adult; Apolipoproteins; Aryldialkylphosphatase; Cholesterol; Diabetes Mellitus, Type 2; Esterases; F | 2001 |
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind | 2002 |
Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind | 2002 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Topics: Blood Glucose; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Gemfib | 1992 |
Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; | 1991 |
Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind | 1990 |
Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Human | 1989 |
17 other studies available for gemfibrozil and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Topics: Albumins; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-R | 2020 |
First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Huma | 2015 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholester | 2016 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.
Topics: Adiponectin; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug | 2013 |
An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Interactions; Estrogen Replacement Therapy; Fatty Acids | 2003 |
Dysregulation of growth hormone in acquired generalized lipodystrophy.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati | 2004 |
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2005 |
Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: an opportunity for pharmacists.
Topics: Ambulatory Care; Day Care, Medical; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gemfi | 2007 |
Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes.
Topics: 6-Ketoprostaglandin F1 alpha; 8,11,14-Eicosatrienoic Acid; Aged; Arachidonic Acid; Cholesterol; Diab | 1998 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dise | 2000 |
Therapy and clinical trials.
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2 | 2000 |
Effect of gemfibrozil on intermediate-density lipoproteins in NIDDM patients. A retrospective study.
Topics: Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoprot | 1992 |
[The effect of gemfibrozil on serum apo C II and C III in diabetic hyperlipidemia].
Topics: Aged; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Diabetes Mellitus, Type 2; Femal | 1991 |
[Effect of gemfibrozil on serum lipids, lipoproteins and apolipoproteins in diabetes mellitus with dyslipidemia].
Topics: Aged; Apolipoproteins; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipi | 1988 |
The hypolipidemic effect of gemfibrozil on hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyp | 1986 |
Gemfibrozil has antilipemic effects on diabetic patients with hyperlipidemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipidemia | 1987 |